Navicixizumab (OMP-305B83) 是一种双特异性抗VEGF和抗DLL4抑制抗体。Navicixizumab 可以与紫杉醇结合用于癌症研究。Navicixizumab 可用于卵巢癌、原发性腹膜癌或输卵管癌的研究。
| 生物活性 | Navicixizumab (OMP-305B83) is a bispecific anti-VEGFand anti-DLL4inhibitory antibody. Navicixizumab can combine withPaclitaxel(HY-B0015) forcancerresearch. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tubecancer[1][2][3]. |
| IC50& Target | IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM) |
体外研究
(In Vitro) | Navicixizumab (0-100 μM) 在 hVEGF 存在的情况下减少人内皮细胞的增殖[3].
|
体内研究
(In Vivo) | Navicixizumab (15 mg/kg，每周一次，持续 4 周) 抑制结肠异种移植肿瘤的生长[3]。
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
